Filing Details
- Accession Number:
- 0001181431-13-062018
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-12-09 19:10:07
- Reporting Period:
- 2013-12-05
- Filing Date:
- 2013-12-09
- Accepted Time:
- 2013-12-09 19:10:07
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1492426 | Horizon Pharma Inc. | HZNP | Pharmaceutical Preparations (2834) | 272179987 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1523672 | N Todd Smith | C/O Horizon Pharma, Inc. 520 Lake Cook Road, Suite 520 Deerfield IL 60015 | Evp & Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-12-05 | 18,037 | $0.00 | 48,933 | No | 4 | A | Direct | |
Common Stock | Acquisiton | 2013-12-09 | 3,350 | $0.00 | 52,283 | No | 4 | M | Direct | |
Common Stock | Disposition | 2013-12-09 | 1,322 | $6.79 | 50,961 | No | 4 | S | Direct | |
Common Stock | Disposition | 2013-12-09 | 10,000 | $6.93 | 40,961 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Restricted stock units | Disposition | 2013-12-09 | 3,350 | $0.00 | 10,048 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
6,698 | No | 4 | M | Direct |
Footnotes
- Fully vested deferred issuance of restricted stock units provided as a one-time bonus payment in connection with the completion of the Company's acquisition of U.S. rights to VIMOVO (R).
- Includes 8,326 shares of the Company's common stock acquired in June 2013 and December 2013 pursuant to an employee stock purchase program.
- Reflects shares of common stock surrendered via open market sale to satisfy tax withholding obligations in connection with vesting of a restricted stock unit and the receipt of a fully vested deferred issuance stock award.
- Each restricted stock units represents a contingent right to receive one share of Horizon Pharma, Inc. common stock.
- On December 8, 2011, the reporting person was granted 13,397 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.